Navigation Links
Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer
Date:9/3/2010

By Steven Reinberg
HealthDay Reporter

THURSDAY, Sept. 2 (HealthDay News) -- People with osteoporosis who take drugs such as Boniva (ibandronate), Fosamax (alendronate) or Actonel (risedronate) to strengthen their bones may be at an increased risk of esophageal cancer, British researchers report.

This class of medicines, called oral bisphosphonates, are the most commonly used drugs to treat osteoporosis and other bone diseases. While anecdotal reports have suggested that they may increase the risk of esophageal cancer, the scientific evidence has been limited, the researchers noted.

"What we lack at present is a full picture of the benefits versus risks for long-term use of bisphosphonates, which are increasingly commonly prescribed," said lead researcher Dr. Jane Green, a clinical epidemiologist, in the Oxford University's Cancer Epidemiology Unit. "Our results are a small part of this picture."

There are no immediate implications for clinical practice, Green stressed.

"Esophageal cancer is uncommon, and even if risk is doubled it is still low" for any one person, she said.

Also, "like any observational study, we cannot be sure that the results reflect a true effect of the drugs -- it could be that people more likely to get cancer are prescribed bisphosphonates [more often] -- although we accounted for the major known possibilities. As usual, more research is needed," Green said.

The report is published in the Sept. 2 online edition of the BMJ.

In the study, Green's team used the UK General Practice Research Database to collect data on almost 3,000 men and women with esophageal cancer, more than 2,000 with stomach cancer and over 10,000 with colorectal cancer diagnosed between 1995 and 2005.

They compared these patients with age- and sex-matched people without these conditions.

The team found people who had had 10 or more prescriptions for bisphosphonates written for them, or had received prescriptions for these drugs over about five years, had almost double the risk of esophageal cancer, compared with people who didn't take these drugs.

Green's group also found an increased risk for stomach or bowel cancer, according to the report.

Usually, esophageal cancer is seen in one of 1,000 people at ages 60-79 over five years. Based on these findings, the researchers estimate that taking oral bisphosphonates over five years increases this to two cases per 1,000 people.

Another recent study that looked at the same link using the same database didn't find an increase in esophageal cancer from bisphosphonates, but this new study followed patients for twice as long as the earlier study and therefore had more "statistical power," the researchers said.

Diane Wysowski, an epidemiologist with the U.S. Food and Drug Administration and author of an accompanying journal editorial, commented that "several adverse esophageal events have been reported with the use of oral bisphosphonates, including erosion and inflammation of the lining of the esophagus, esophageal stricture and perforation, and esophageal cancer."

If the results from this study are confirmed and oral bisphosphonates double the rate of esophageal cancer, esophageal cancer rates would still remain relatively low from a population standpoint, she said.

"However, because oral bisphosphonates are widely used on a chronic basis, the results, if confirmed, could have implications for a large number of patients," Wysowski said.

The possibility of adverse effects on the esophagus should prompt doctors who prescribe these drugs to consider risks vs. benefits, ask patients about digestive disorders before prescribing, and to reinforce directions for use on the basis of each individual product, she said.

Wysowski advises patients to: "Be sure to follow the directions for use and report to your doctor any difficulty swallowing or throat, chest, or digestive discomfort so that your doctor can evaluate the need for oral bisphosphonate discontinuation."

More information

For more on osteoporosis, go to the U.S. National Library of Medicine.

SOURCES: Jane Green, M.D., Ph.D., clinical epidemiologist, Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, England; Diane Wysowski, Ph.D., epidemiologist, U.S. Food and Drug Administration; Sept. 2, 2010, BMJ, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Battlefield camaraderie yields long-term dividends for veterans, study finds
2. Newer cornea transplant surgery shows short- and long-term promise
3. Proton beam therapy shows encouraging long-term outcome for patients with locally advanced sinonasal cancers
4. Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding
5. Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
6. Options to Integrate Health and Long-Term Care for Dual Eligibles
7. Long-Term Use of Osteoporosis Drugs Linked to Fractures
8. Plaque on CT scan is strong predictor of heart disease, worse long-term outcomes
9. Increased radiation dose does not increase long-term side effects for prostate cancer patients
10. Health Care Reform Bill Will Also Improve Long-Term Care
11. Long-Term Breast-Feeding Tied to More Aggressive Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer
(Date:4/29/2017)... ... 29, 2017 , ... Phytomer USA is pleased to introduce Jennifer Smith as ... Smith’s role is to provide excellent customer service, support, training and knowledge to spa ... comes to Phytomer with a wealth of industry experience including roles as spa manager ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... (The National Campaign) announces its support for the Access to Contraception for ... Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that ...
(Date:4/28/2017)... ... , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today ... outlook as “stable.” At the same time, the ratings agency cautioned that the company’s ... below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to ...
(Date:4/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... board election process has been in place since the RBMA was founded in 1968 ... FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
Breaking Medicine Technology: